UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells
Authors:
Open Access
- 1 January 2019
- journal article
- retracted article
- Published by Wiley in Journal of Oncology
- Vol. 2019, 1-15
Abstract
Objectives. Cisplatin (DDP) is one of the most commonly used chemotherapeutic drugs for several cancers, including non-small-cell lung cancer (NSCLC). However, resistance to DDP eventually develops, limiting its further application. New therapy targets are urgently needed to reverse DDP resistance.Methods. The mRNA expression of UBE2C,ZEB1/2,ABCG2, and ERCC1was analyzed by reverse transcription-polymerase chain reaction. The protein levels of these molecules were analyzed by Western blotting and immunofluorescent staining. Cell proliferation was detected by CCK8 and MTT assays. Cell migration and invasion were analyzed by wound healing assay and Transwell assays. Promoter activities and gene transcription were analyzed by luciferase reporter assay.Results.In this study, we examined the effect of UBE2C and ZEB1/2 expression levels in DDP-resistant cells of NSCLC. We confirmed that aberrant expression of UBE2C and ZEB1/2 plays a critical role in repressing the DDP sensitivity to NSCLC cells. Additionally, knockdown of UBE2C significantly sensitized resistant cells to DDP by repressing the expression of ZEB1/2. Mechanistic investigations indicated that UBE2C transcriptionally regulated ZEB1/2 by accelerating promoter activity. This study revealed that ZEB1/2 promotes the epithelial mesenchymal transition and expression of ABCG2 and ERCC1 to participate in UBE2C-mediated NSCLC DDP-resistant cell progression, metastasis, and invasion.Conclusion. UBE2C may be a novel therapy target for NSCLC for sensitizing cells to the chemotherapeutic agent DDP.Keywords
Funding Information
- National Natural Science Foundation of China (31801085, ZR2018QH004, ZR2016HB55, ZR2017LH072, ZR2017PH067, 2017WS154, BY2015KYQD25, BY2015KJ14)
- Natural Science Foundation of Shandong Province (31801085, ZR2018QH004, ZR2016HB55, ZR2017LH072, ZR2017PH067, 2017WS154, BY2015KYQD25, BY2015KJ14)
- Shandong Provincial Pharmaceutical Technology Development Plan (31801085, ZR2018QH004, ZR2016HB55, ZR2017LH072, ZR2017PH067, 2017WS154, BY2015KYQD25, BY2015KJ14)
- Research Foundation of Binzhou Medical University (31801085, ZR2018QH004, ZR2016HB55, ZR2017LH072, ZR2017PH067, 2017WS154, BY2015KYQD25, BY2015KJ14)
This publication has 51 references indexed in Scilit:
- EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancerBMC Cancer, 2012
- Processive ubiquitin chain formation by the anaphase-promoting complexSeminars in Cell & Developmental Biology, 2011
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerOncogene, 2010
- Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formationJournal of Cell Biology, 2010
- Building ubiquitin chains: E2 enzymes at workNature Reviews Molecular Cell Biology, 2009
- The Unique N Terminus of the UbcH10 E2 Enzyme Controls the Threshold for APC Activation and Enhances Checkpoint Regulation of the APCMolecular Cell, 2008
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nature Reviews Cancer, 2007
- Cyclooxygenase-2–Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non–Small Cell Lung CancerCancer Research, 2006